Skip to main content

Table 2 Treatment characteristics

From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer

Imaging method prior to MDT, n (%)

 

PSMA-PET/CT

73 (91.3%)

Choline-PET/CT

3 (3.8%)

Bone scan with or without CT/MRI, n (%)

4 (5.0%)

PSA at imaging (ng/ml), median (range)

1.24 (0.07–1252)

Number of metastases, n (%)

 One metastasis

53 (66.3%)

 Two metastases

20 (25.0%)

 Three metastases

6 (7.5%)

 Four metastases

1 (1.3%)

Metastatic site, number of lesions (%)

 Skull

2 (0.7%)

 Thoracic (ribs/clavicles/sternum)

52 (45.2%)

 Spine

12 (10.4%)

 Pelvis including sacral bone

45 (39.1%)

 Extremities

4 (3.5%)

Type of treatment, n (%)

 MDT alone

49 (61.3%)

 MDT + salvage RT to prostate bed and/or local recurrence and/or pelvis and regional LN

21 (26.3%)

 MDT + definitive RT to primary

10 (12.5%)

Pre-MDT PSA (ng/ml), median (range)

1.23 (0.07–1252)

Pre-MDT PSA-DT (month), median (range)

4.1 (0.7–34.0)

Dose prescription

 40 Gy/10 fractions (BED3: 93.3 Gy)

n = 45 (56.3%)

 30 Gy/5 fractions (BED3: 90 Gy)

n = 17 (21.3%)

 50.4 Gy/28 fractions (BED3: 80.6 Gy)

n = 6 (7.5%)

 56 Gy/28 fractions (BED3: 93.3 Gy)

n = 3 (3.8%)

 35 Gy/10 fractions (BED3: 75.8 Gy)

n = 2 (2.5%)

 50 Gy/25 fractions (BED3: 83.3 Gy)

n = 2 (2.5%)

 55 Gy/25 fractions (BED3: 95.3 Gy)

n = 1 (1.3%)

 52,8 Gy/32 fractions (BED3: 81.8 Gy)

n = 1 (1.3%)

 50 Gy/20 fractions (BED3: 91.7 Gy)

n = 1 (1.3%)

 42 Gy/14 fractions (BED3: 84.0 Gy)

n = 1 (1.3%)

 39 Gy/13 fractions (BED3: 78.0 Gy)

n = 1 (1.3%)

Concomitant ADT, n (%)

55 (68.8%)

  1. ADT, androgen deprivation therapy; BED, biologically effective dose; CT, computed tomography; MDT, metastasis-directed therapy; MRI, magnetic resonance imaging; PET, positron emission tomography; PSA, prostate specific antigen; PSA-DT, PSA-doubling time; PSMA, prostate specific membrane antigen; RT, radiotherapy